Minneapolis-based Humanetics Corp., specializing in radiation resistance, has been awarded $3.8 million in grant funding from the U.S. Department of Defense (DOD) to advance BIO 300, a revolutionary drug aimed at protecting individuals from radiation exposure, a Business Wire article said.
BIO 300 originated in the DOD by researchers at the Armed Forces Radiobiology Research Institute and was subsequently licensed to Humanetics for development with applications for military use, the article said. The company is currently running a clinical trial to assess the oral medication’s potential for abating toxicity accompanying standard cancer treatments.
“We are very excited that the DOD continues to support BIO 300 as a drug that can be used to protect military personnel and civilians at risk of radiation exposure,” Humanetics CEO Ronald Zenk said in the article. “We are constantly working toward making this therapy available in ways that support the many disparate populations at risk of radiation exposure.”
BIO 300 formulations could prove critically important in an era of growing global concerns about radiological technology, Michael Kaytor, vice president of research and development at Humanetics, said in the article.
“In light of increasing geopolitical pressures regarding the potential use of radiological or nuclear weaponry, the protection of our armed forces from radiation exposure and enabling them to operate in areas of possible concern is a strategic imperative,” Kaytor said in the article.